Bioporto ASOCSE:BIOPOR -1.74%69 Market Cap is kr559.46 Mil as of Jul. 05, 2026. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 69/100 and a GF Value™ of kr1.23 (Fairly Valued). The stock has 3 warning signs investors should review. Among 219 Medical Diagnostics & Research companies, Bioporto AS ranks better than 52.97% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bioporto AS's share price for the quarter that ended in Dec. 2025 was kr1.02. Bioporto AS's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 495.10 Mil. Therefore, Bioporto AS's market cap for the quarter that ended in Dec. 2025 was kr505.00 Mil.
Bioporto AS's quarterly market cap
declined
from Jun. 2025 (kr638.34 Mil) to Sep. 2025 (kr589.24 Mil) and
declined
from Sep. 2025 (kr589.24 Mil) to Dec. 2025 (kr505.00 Mil).
Bioporto AS's annual market cap
declined
from Dec. 2023 (kr793.48 Mil) to Dec. 2024 (kr665.97 Mil) and
declined
from Dec. 2024 (kr665.97 Mil) to Dec. 2025 (kr505.00 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bioporto AS's Enterprise Value for Today is kr512.09 Mil.
Bioporto AS (OCSE:BIOPOR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bioporto AS Market Cap Related Terms
Bioporto AS Market Cap Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:BIOPOR vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bioporto AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (OCSE:BIOPOR) has a Market Cap of kr559.46 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #103 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 47%.
Is Bioporto AS's Market Cap too high?
Bioporto AS's current Market Cap is kr559.46 Mil. Based on the distribution chart, Bioporto AS ranks #103 out of 219 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #103 out of 219 companies for Market Cap. This puts Bioporto AS in the upper half of its industry. The industry median Market Cap is 59.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 59.06, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 59.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Market Cap is kr559.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Fairly Valued. The stock's GF Value™ is kr1.23, compared to a current price of kr1.13 — trading 8.1% below its estimated fair value. The current Market Cap is kr559.46 Mil. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current Market Cap is kr559.46 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of kr1.13 is trading 8.1% below its estimated GF Value™ of kr1.23.
GuruFocus considers Bioporto AS to be Fairly Valued.
Key valuation signals for OCSE:BIOPOR:
Market Cap: kr559.46 Mil
GF Value™: kr1.23 vs. price of kr1.13 (8.1% below fair value)
No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score
Get the complete analysis for OCSE:BIOPOR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BIOPOR has been successfully added to your 
